Are apolipoproteins A and B better than lipoproteins for assessing risk of obstructive coronary heart disease?

Detalhes bibliográficos
Autor(a) principal: Manfroi,Waldomiro Carlos
Data de Publicação: 1999
Outros Autores: Zago,Alcides José, Campos,Marcelo, Alves,Alexandre, Brisolara,Maria Lúcia, Souza,Josiane de, Candiago,Rafael Henriques, Kirschnick,Luciana, Ribeiro,Letícia, Ordovás,Kárem, Leitão,Cristiane, Cruz,Rosana
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Arquivos Brasileiros de Cardiologia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X1999000600001
Resumo: OBJECTIVE: To evaluate whether apolipoproteins A-I (Apo A-I) and B (Apo B) have, higher ensitivity (SN), specificity (SP) and positive predictive value (PPV) than lipoproteins (LP), total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL), very low density lipoprotein (VLDL), and triglycerides (TGL) in assessing the risk of coronary heart disease (CHD). METHODS: This is a transversal case-control study of 241 patients, who were divided into two groups: 1) 145 patients with CHD, and 2) 96 patients without coronary disease. A model of logistic regression to evaluate the relation between the LPs and CHD was developed in which variables with a p-alpha <0.1 were included. RESULTS: Apo A-I levels were higher in the patients without CHD, (OR 2.08, CI 1.20-3.57). There were no statistical differences between the values of Apo A-I and the remaining lipid fractions (Apo A-I: 67%; Apo B: 100%; PPV: TC= 71%; TGC=71%; HDL=71%; LDL=71%). The costs of the tests in Reais were as follows: Apo A-I: R$ 56.60; Apo B-100: R$ 56.60; TC: R$ 9.94; HDL: R$ 21.30; LDL: R$ 28.40; TGL: R$ 14.20. CONCLUSION: Levels of Apo A-I and Apo B have no advantage over conventional lipoproteins in predicting the risk of CHD, despite the statistical association between Apo A-I and CHD; in addition, their costs are higher than those of the conventional lipoproteins.
id SBC-1_2d430dd6db83cfa9a2d12c61b1ecc24f
oai_identifier_str oai:scielo:S0066-782X1999000600001
network_acronym_str SBC-1
network_name_str Arquivos Brasileiros de Cardiologia (Online)
repository_id_str
spelling Are apolipoproteins A and B better than lipoproteins for assessing risk of obstructive coronary heart disease?risk factorscoronary heart diseaselipoproteinsOBJECTIVE: To evaluate whether apolipoproteins A-I (Apo A-I) and B (Apo B) have, higher ensitivity (SN), specificity (SP) and positive predictive value (PPV) than lipoproteins (LP), total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL), very low density lipoprotein (VLDL), and triglycerides (TGL) in assessing the risk of coronary heart disease (CHD). METHODS: This is a transversal case-control study of 241 patients, who were divided into two groups: 1) 145 patients with CHD, and 2) 96 patients without coronary disease. A model of logistic regression to evaluate the relation between the LPs and CHD was developed in which variables with a p-alpha <0.1 were included. RESULTS: Apo A-I levels were higher in the patients without CHD, (OR 2.08, CI 1.20-3.57). There were no statistical differences between the values of Apo A-I and the remaining lipid fractions (Apo A-I: 67%; Apo B: 100%; PPV: TC= 71%; TGC=71%; HDL=71%; LDL=71%). The costs of the tests in Reais were as follows: Apo A-I: R$ 56.60; Apo B-100: R$ 56.60; TC: R$ 9.94; HDL: R$ 21.30; LDL: R$ 28.40; TGL: R$ 14.20. CONCLUSION: Levels of Apo A-I and Apo B have no advantage over conventional lipoproteins in predicting the risk of CHD, despite the statistical association between Apo A-I and CHD; in addition, their costs are higher than those of the conventional lipoproteins.Sociedade Brasileira de Cardiologia - SBC1999-06-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X1999000600001Arquivos Brasileiros de Cardiologia v.72 n.6 1999reponame:Arquivos Brasileiros de Cardiologia (Online)instname:Sociedade Brasileira de Cardiologia (SBC)instacron:SBC10.1590/S0066-782X1999000600001info:eu-repo/semantics/openAccessManfroi,Waldomiro CarlosZago,Alcides JoséCampos,MarceloAlves,AlexandreBrisolara,Maria LúciaSouza,Josiane deCandiago,Rafael HenriquesKirschnick,LucianaRibeiro,LetíciaOrdovás,KáremLeitão,CristianeCruz,Rosanaeng2002-01-08T00:00:00Zoai:scielo:S0066-782X1999000600001Revistahttp://www.arquivosonline.com.br/https://old.scielo.br/oai/scielo-oai.php||arquivos@cardiol.br1678-41700066-782Xopendoar:2002-01-08T00:00Arquivos Brasileiros de Cardiologia (Online) - Sociedade Brasileira de Cardiologia (SBC)false
dc.title.none.fl_str_mv Are apolipoproteins A and B better than lipoproteins for assessing risk of obstructive coronary heart disease?
title Are apolipoproteins A and B better than lipoproteins for assessing risk of obstructive coronary heart disease?
spellingShingle Are apolipoproteins A and B better than lipoproteins for assessing risk of obstructive coronary heart disease?
Manfroi,Waldomiro Carlos
risk factors
coronary heart disease
lipoproteins
title_short Are apolipoproteins A and B better than lipoproteins for assessing risk of obstructive coronary heart disease?
title_full Are apolipoproteins A and B better than lipoproteins for assessing risk of obstructive coronary heart disease?
title_fullStr Are apolipoproteins A and B better than lipoproteins for assessing risk of obstructive coronary heart disease?
title_full_unstemmed Are apolipoproteins A and B better than lipoproteins for assessing risk of obstructive coronary heart disease?
title_sort Are apolipoproteins A and B better than lipoproteins for assessing risk of obstructive coronary heart disease?
author Manfroi,Waldomiro Carlos
author_facet Manfroi,Waldomiro Carlos
Zago,Alcides José
Campos,Marcelo
Alves,Alexandre
Brisolara,Maria Lúcia
Souza,Josiane de
Candiago,Rafael Henriques
Kirschnick,Luciana
Ribeiro,Letícia
Ordovás,Kárem
Leitão,Cristiane
Cruz,Rosana
author_role author
author2 Zago,Alcides José
Campos,Marcelo
Alves,Alexandre
Brisolara,Maria Lúcia
Souza,Josiane de
Candiago,Rafael Henriques
Kirschnick,Luciana
Ribeiro,Letícia
Ordovás,Kárem
Leitão,Cristiane
Cruz,Rosana
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Manfroi,Waldomiro Carlos
Zago,Alcides José
Campos,Marcelo
Alves,Alexandre
Brisolara,Maria Lúcia
Souza,Josiane de
Candiago,Rafael Henriques
Kirschnick,Luciana
Ribeiro,Letícia
Ordovás,Kárem
Leitão,Cristiane
Cruz,Rosana
dc.subject.por.fl_str_mv risk factors
coronary heart disease
lipoproteins
topic risk factors
coronary heart disease
lipoproteins
description OBJECTIVE: To evaluate whether apolipoproteins A-I (Apo A-I) and B (Apo B) have, higher ensitivity (SN), specificity (SP) and positive predictive value (PPV) than lipoproteins (LP), total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL), very low density lipoprotein (VLDL), and triglycerides (TGL) in assessing the risk of coronary heart disease (CHD). METHODS: This is a transversal case-control study of 241 patients, who were divided into two groups: 1) 145 patients with CHD, and 2) 96 patients without coronary disease. A model of logistic regression to evaluate the relation between the LPs and CHD was developed in which variables with a p-alpha <0.1 were included. RESULTS: Apo A-I levels were higher in the patients without CHD, (OR 2.08, CI 1.20-3.57). There were no statistical differences between the values of Apo A-I and the remaining lipid fractions (Apo A-I: 67%; Apo B: 100%; PPV: TC= 71%; TGC=71%; HDL=71%; LDL=71%). The costs of the tests in Reais were as follows: Apo A-I: R$ 56.60; Apo B-100: R$ 56.60; TC: R$ 9.94; HDL: R$ 21.30; LDL: R$ 28.40; TGL: R$ 14.20. CONCLUSION: Levels of Apo A-I and Apo B have no advantage over conventional lipoproteins in predicting the risk of CHD, despite the statistical association between Apo A-I and CHD; in addition, their costs are higher than those of the conventional lipoproteins.
publishDate 1999
dc.date.none.fl_str_mv 1999-06-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X1999000600001
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X1999000600001
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0066-782X1999000600001
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Cardiologia - SBC
publisher.none.fl_str_mv Sociedade Brasileira de Cardiologia - SBC
dc.source.none.fl_str_mv Arquivos Brasileiros de Cardiologia v.72 n.6 1999
reponame:Arquivos Brasileiros de Cardiologia (Online)
instname:Sociedade Brasileira de Cardiologia (SBC)
instacron:SBC
instname_str Sociedade Brasileira de Cardiologia (SBC)
instacron_str SBC
institution SBC
reponame_str Arquivos Brasileiros de Cardiologia (Online)
collection Arquivos Brasileiros de Cardiologia (Online)
repository.name.fl_str_mv Arquivos Brasileiros de Cardiologia (Online) - Sociedade Brasileira de Cardiologia (SBC)
repository.mail.fl_str_mv ||arquivos@cardiol.br
_version_ 1752126550899163136